COLL GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Collegium Pharmaceutical Inc
Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts.
Current Price
$33.78
-3.01%GoodMoat Value
$106.16
214.3% undervaluedProfile
Valuation (TTM)
Market Cap$1.07B
P/E14.31
EV—
P/B3.56
Shares Out31.75M
P/Sales1.35
Revenue$796.33M
EV/EBITDA7.60
Collegium Pharmaceutical Inc (COLL) Quality Analysis
COLL Profitability
Profitability trend analysis coming soon
COLL Growth
Growth trend analysis coming soon
COLL Financial Health
Financial health indicators coming soon
COLL Quality & Fundamental Analysis
Collegium Pharmaceutical Inc (COLL) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ. This quality analysis page evaluates Collegium Pharmaceutical Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Collegium Pharmaceutical Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 9.41% and a return on equity (ROE) of 24.84%. Return on assets (ROA) stands at 4.52%.
The debt-to-equity ratio is 2.70, with a current ratio of 1.57. Operating margin is 22.86%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Collegium Pharmaceutical Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.